Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of CanProFem-AK in Healthy Volunteers
NCT06535126Phase 1Completed
- Sponsor
- Industrial Microbiology
- Start
- Jun 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of roseofungin in vaginal candidiasis, sponsored by Industrial Microbiology. Primary endpoints: General indicators for safety evaluation of a studied drug at 24 hours and Tolerability of the studied drug at 24 hours. Started Jun 2024; status: completed.
02
Drugs
roseofungin
03
Conditions
vaginal candidiasis
Beyond the preview
Go deeper on NCT06535126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06535126.